IDbyDNA to Present at the Digital Medicine and Medtech Showcase 2019
SAN FRANCISCO--(BUSINESS WIRE)--Dec 20, 2018--IDbyDNA, a metagenomics technology company providing more actionable Infectious Disease test results, today announced that it will present at the Digital Medicine and Medtech Showcase 2019, occurring January 7-9, 2019 at the Parc 55 in San Francisco.
Guochun Liao, Ph.D., IDbyDNA’s Founder, President & Chief Executive Officer, is scheduled to present on Wednesday, January 9 at 10:30 am PST, in the Powell – I track.
“Our recent achievements have demonstrated our ability to expand microbial profiling and pathogen detection in a reliable and efficient manner,” said Dr. Liao. “We are rapidly developing commercial partnerships worldwide, which extend our reach and provide physicians and patients with access to our Explify technology platform to enable the detection, identification, and classification of bacteria, viruses, fungi, and parasites. Our ongoing collaboration with top tier medical institutions continues to yield clinical evidence and know how to guide new product development. I am thrilled at the progress we have made thus far and look forward to continue helping our healthcare partners accurately identify the origin of patients’ diseases.”
About Explify The Explify Platform simultaneously profiles tens of thousands of microorganisms and pathogens in any sample to deliver actionable information to healthcare providers. This turn-key solution enables clinical laboratories to offer NGS-based metagenomics testing for infectious disease. From sample preparation to report delivery, the Explify Platform manages laboratory workflow, analyzes metagenomics data, and provides applications for clinical review, quality control and reporting. The Explify Platform offers clinical laboratories a streamlined path to offering unbiased, NGS-based Infectious Disease tests that are more comprehensive, and more accurate than conventional tests. Explify metagenomics analysis is a proprietary DNA search engine that analyzes tens of millions of Next-Generation Sequencing reads within minutes to enable the detection of tens of thousands of microorganisms. The proprietary Explify database includes millions of curated DNA and RNA reference sequences and can identify more than 50,000 microorganisms and over 3,000 known common and rare pathogens.
About IDbyDNA I DbyDNA has developed transformative metagenomics technology to simultaneously profile tens of thousands of microorganisms and pathogens in any sample. Our turn-key Explify Platform easily integrates into medical laboratories to deliver actionable information to healthcare providers. Working with our global partners, we are setting the standard for the identification and understanding of microorganisms and their role in human health. http://www.idbydna.com/
View source version on businesswire.com:https://www.businesswire.com/news/home/20181220005103/en/
CONTACT: Shai Biran, Ph.D.
MacDougall Biomedical Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: TECHNOLOGY GENETICS CLINICAL TRIALS SOFTWARE BIOTECHNOLOGY PHARMACEUTICAL HEALTH
Copyright Business Wire 2018.
PUB: 12/19/2018 06:20 PM/DISC: 12/20/2018 08:30 AM